【drug-news】【资讯翻译】Sun以6亿美元的价格与Taro达成协议
这个帖子发布于 12 年零 315 天前，其中的信息可能已发生改变或有所发展。
http://www.fiercepharma.com/story/sun-finally-nabs-taro-600m-deal/2012-08-13
认领翻译的战友请跟帖注明“认领本文翻译，48小时内未完成，请其他战友认领！”
请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分
请根据自己的专业背景选择相应的资讯认领，经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！
新近参与本次活动的会员请查看：【公告】动态版重启资讯翻译计划：我为人人，人人为我，共同提高
寻找最近的翻译贴请查看：http://search.dxy.cn/?words=%E8%B5%84%E8%AE%AF%E7%BF%BB%E8%AF%91&bid=116&t=1&c=1&age=7&bid=116&limit=30&o=1
翻译时请参照版规 【版务】科技动态版版规及加分细则（ 2014-02-21 更新）
希望参与动态版其他活动的会员请查看版面右边栏的置顶部分
It took years of bargaining, but India's Sun Pharmaceuticals and Israel's Taro Pharmaceuticals finally reached a buyout détente. The two generics makers shook hands on a $39.50-per-share cash deal.
For that $600 million, Sun gets the 34% of Taro it doesn't already own. If the deal meets shareholder approval, Taro will go private and delist from the New York Stock Exchange. And Taro will finally fit completely under Sun's wing.
Emphasis should be placed on the word "finally." The companies played hardball for more than three years in a contentious battle that, at one point, found its way to the Israeli Supreme Court. Last month, Taro scoffed at Sun's most recent offer of $24.50 per share, calling it "inadequate."
Obviously, Taro had a point. To win the company over, Sun hiked that offer by $15 per share.
Taro reaped $436 million in generics sales last year, earning a spot on FiercePharma's list of the fastest-growing generics companies. Sun also made that list, and, with 150 new approval applications pending and an appetite for more acquisitions, could keep pace for next year's. A potential merger with Germany's Stada Arzneimittel is on the grapevine, but Sun execs say they're most interested in the U.S., Latin America, and Russia.
Taro trading closed Friday at $40.97 per share, as revenues jumped 43% to $159 million last quarter, according to The Economic Times. As the publication points out, delisting Taro would come as the generics maker's stock performance is peaking.
认领翻译的战友请跟帖注明“认领本文翻译，48小时内未完成，请其他战友认领！”
请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分
请根据自己的专业背景选择相应的资讯认领，经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！
新近参与本次活动的会员请查看：【公告】动态版重启资讯翻译计划：我为人人，人人为我，共同提高
寻找最近的翻译贴请查看：http://search.dxy.cn/?words=%E8%B5%84%E8%AE%AF%E7%BF%BB%E8%AF%91&bid=116&t=1&c=1&age=7&bid=116&limit=30&o=1
翻译时请参照版规 【版务】科技动态版版规及加分细则（ 2014-02-21 更新）
希望参与动态版其他活动的会员请查看版面右边栏的置顶部分
It took years of bargaining, but India's Sun Pharmaceuticals and Israel's Taro Pharmaceuticals finally reached a buyout détente. The two generics makers shook hands on a $39.50-per-share cash deal.
For that $600 million, Sun gets the 34% of Taro it doesn't already own. If the deal meets shareholder approval, Taro will go private and delist from the New York Stock Exchange. And Taro will finally fit completely under Sun's wing.
Emphasis should be placed on the word "finally." The companies played hardball for more than three years in a contentious battle that, at one point, found its way to the Israeli Supreme Court. Last month, Taro scoffed at Sun's most recent offer of $24.50 per share, calling it "inadequate."
Obviously, Taro had a point. To win the company over, Sun hiked that offer by $15 per share.
Taro reaped $436 million in generics sales last year, earning a spot on FiercePharma's list of the fastest-growing generics companies. Sun also made that list, and, with 150 new approval applications pending and an appetite for more acquisitions, could keep pace for next year's. A potential merger with Germany's Stada Arzneimittel is on the grapevine, but Sun execs say they're most interested in the U.S., Latin America, and Russia.
Taro trading closed Friday at $40.97 per share, as revenues jumped 43% to $159 million last quarter, according to The Economic Times. As the publication points out, delisting Taro would come as the generics maker's stock performance is peaking.
